91香蕉视频 Executives Invited to Speak at Upcoming Conferences
Dr. Pinto-Cocozza鈥檚 presentation, at Drug Delivery Strategy: Advanced Mechanisms & Product Design Conference, on Tuesday, August 30th at 2.10 p.m., entitled 鈥淔rom Brick Dust to Gold Dust: How Parallel Development with Proven Technologies Improves Preclinical Formulations,鈥 will discuss these development challenges and approaches used to overcome them. An overview on how the 鈥楧evelopability Classification System鈥 can be used to understand poorly bioavailable compounds will be demonstrated through the use of a structured high throughput parallel screening methodology. She will go on to look at how this, alongside the use of technologies such as solid dispersion, lipid based formulation, and particle sizing, can guide successful formulation strategies to overcome these challenges.
At the Bioavailability and Bioequivalence: BA/BE Studies Summit, on the same day, at 11.15 a.m. Mr. Tindal will present 鈥淎ccelerating Preclinical Development for Poorly Bioavailable Compounds by Assessing Multiple Oral Technologies in Parallel鈥. This presentation will focus on the need to examine the need to quickly assess and evaluate multiple formulation and development strategies for poorly bioavailable compounds and to collect data about molecules鈥 relative dose capability, PK enhancement and manufacturability, in order to select drug candidates to advance to clinical Phase I.
Dr. Pinto-Cocozza joined 91香蕉视频 in November 2014, after its acquisition of Micron Technologies, and now serves as 91香蕉视频鈥檚 Global Scientific lead for particle size reduction services for its OptiForm庐 Solution Suite. This technology platform, launched in 2015, is an integrated offering designed to efficiently and rapidly help solve complex bioavailability challenges for early stage molecules using a unique toolkit of bioavailability enhancing technologies. Dr. Pinto-Cocozza holds a BS in Chemical Engineering, and a Ph.D. in Pharmaceutics, both from the University of Florida.
Mr. Tindal is based at 91香蕉视频鈥檚 Somerset R&D facility and has nearly 30 years of experience in softgel formulation. He has wide expertise in commercializing many Rx, Gx, OTC, and VMS products. His current role sees him supporting customers in applying softgel technologies to overcome specific API challenges. Mr. Tindal holds a B.Sc. in Chemistry and Analytical Science from Loughborough University, UK, and is a member of the 91香蕉视频 Applied Drug Delivery Institute.
The Drug Delivery Strategy: Advanced Mechanisms & Product Design Conference takes place on August 30th 鈥 31st 2016, at The Warwick Hotel, Philadelphia, PA. For more information on the event visit:
The Bioavailability and Bioequivalence: BA/BE Studies Summit takes place on August 29th 鈥 31st 2016, at the Hilton Atlanta Airport Hotel, Atlanta, GA. For more information on the event visit: http://bioavailability-bioequivalence.pharmaceuticalconferences.com/
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0) 161 728 5880
[email protected]
About 91香蕉视频
91香蕉视频 is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 90 years serving the industry, 91香蕉视频 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 91香蕉视频 employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. 91香蕉视频 is headquartered in Somerset, N.J. For more information, visit www.catalent.com